The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
This is the placing holder who NFX BOD negotiated with and know who they are. Therefore the BOD have a duty also to provide the market accordingly as they know the placing holder. It’s different when it’s a pi who is more difficult to find on the share register!
Why are Nuformix hiding the placing holding institution who bought 4/5% of the holding at 0.2p yet don’t announce their position as per requirement? Guess they just flogging in the background as Lanstead etc use their MM control to manipulate the tiny SP to drip feed to those gullible enough to throw cash in the hole!
There is a lot of nervous holders here trying very hard to drown out real issues and questions here.
Most of these are people who jumped in thinking this would be the easiest 10 bagger out there without reading the very very long history of trying to achieve anything here..
Company is very much on its last hurrah in getting a chance to do anything significant with what little they generated.
As you keep being told to look out there at other data produced by other companies in China etc regarding Tranilast that Nuformix want to try latch onto as their very limited trial data is that!! Limited so to negotiate they need to talk about other peoples data which they won’t have proper access to without paying cash!
Cash cash cash where is the cash etc… tick tick tick as the money drains out of the pot.
Lol, it’s been available for 3 years and the data is not unequivocally good!!!
The rat data is more detailed that’s why it cost a million etc and it’s got a massive X marking bad durability of action.
That is a fact!! It’s a problematic issue!
Looking ahead you will have plenty of opportunities to buy if you love this company over the coming months. Why rush like all the others it will need to gain funds prior to any deals as the purse is empty. March23 results are behind payments which they need to make for the latest tests. They start at around £250,000 plus. Do the maths. Then add running costs and paying accountants and the virtual BOD who are here to take their wages.
Q&A is a desperation to try maintain some kind of noise and interest here whilst Lanstead continue their monthly selling till Aug/Sep when the final payments of the 20 months which started Dec 21!
After that the company has ZERO income and will rapidly fall into cessation unless funding is done, hence Sept AGM.
That’s a long time to try keep holders holding and hence an importance to try maintain current SP before it becomes completely worthless.
Absolutely no need to be buying here until funding is done.
Https://find-and-update.company-information.service.gov.uk/company/12970979/officers
It’s done in a way that deflected attention and paints a picture that Chris/Anne/Alistair/Kirk etc look to be the issue but when you look at the dates and then look at who dissolved it and who they are and what they operate you can see that is not the picture.
“Oxilio Acquisition of LSHS Consulting
Oxford, 30th March 2022 – Oxilio, the pioneering oncology company, repurposing existing drugs to address unmet needs in cancer therapy, today announces that it has acquired LSHS Consulting Limited in a share transaction.
LSHS is a specialist life science consultancy firm established by Dr Dan Gooding, comprising intellectual property assets relevant to Oxilio’s OXL001 programme.
Dr Gooding was CEO of Nuformix plc until June 2020 and has significant experience in the pre-clinical and clinical development of formulations relevant to OXL001. Through him, Oxilio commenced discussions for the licensing of Nuformix’s NXP-001 cocrystal aprepitant formulation for the treatment of cancer.
Dr Gooding has been instrumental in helping Oxilio make rapid scientific and commercial progress with both our co-crystal and lipid-based formulation routes, in addition to the exploration of further formulation technologies which remain under evaluation.
Dr Gooding also introduced Oxilio to TRx Biosciences and facilitated the negotiation of our exclusive licence to use TRX’s lipid platform technology with our aprepitant formulation, again for the treatment of cancer. Since that time, Dr Gooding has become a Director of TRx Biosciences.
As a result of the transaction, Oxilio secures continuing access to Dr Gooding’s expertise and know-how in both our lipid and co-crystal product development routes.
Dr Gooding has undertaken much of our formulation development work with the TRx scientists and provided the additional capability and expertise Oxilio requires to transfer this technology to Quotient Sciences for clinical trials.
We are looking forward to continuing close co-operation with Dr Gooding across a range of scientific developments at Oxilio.”
The more I hear the more it just confirms the desperation to try find a company that is willing to buy what is left here.
They just are not interested in this product in investing 10’s millions to try get it to market when it’s taken too long and too many other therapies in this space now moving closer to changing the space.
Unfortunately it’s taken too long to just get early clinical data done and now they cannot take it further as they have no funds to do that.
The end
“Following the success achieved in these studies the Company's next steps include:
· Investigation of inflammation-related biomarkers in the same tissue sample sets to confirm additional mechanistic and anti-inflammatory benefits on top of SoC's, given the positive anti-fibrotic response;
· Expansion of the current study to include tissue from an additional two further human IPF tissue donors to demonstrate the robustness of NXP002's anti-fibrotic response alone and in SoC combinations in multiple patients; and
· To consider the expansion of the Company's on-going healthy lung tissue study investigating NXP002's duration of action to three donors, based on results when received.”
You think that was free lol
Issue always has been money here.
The product has always had the ability to produce good data but without the structure behind it they lose a lot of potential.
All you have now is a basic stripped out opportunity of NXP002 that has been available now to take since 2019 when it produce human lung tissue data then.
We haven’t moved anywhere here but waste more time and money and destroyed the platform that built NFX as a possibility.
They need money to do anything.
Sorry but listening to the funding part in the interview it was exceptionally weak indeed.
He mentions they have to have a partner which is obvious.
He mentions their results out June 30th where they will show their back dated cash position which will not probably show the actual current condition of cash.
He again waffles on about their lean running costs as it involves paying 3 executives a paltry sim to keep the virtual business going which is basically Dan home desk and Zoom calls plus paying broker and accountant costs plus paying Newcastle for their limited work.
They need more work to get the results and data ready to present and Dan and Julian are then going out waving flags at companies like AZ which are not interested now.
This is going nowhere and they need to raise funds. End of.
If anyone was interested the last funding would not have happened. As Dan said they will now start asking. Therefore absolutely nobody is currently in discussions and NFX need cash asap. Contracts and negotiations take many months even if they find a partner.
We have heated loads of promises over the years here and I have never seen any actually happen.
The max number t could raise was 10% so half done and to get them to do it they had to give the other half as options.
To raise more they need a vote. So now that’s the next stage and no they don’t have cash hence delaying results.
Honestly daft to think otherwise as they need 70k just to try cover overspending as we speak.
All expected and nothing has really changed. The issue is money. Company has nothing and will need to do a proper raise. Said it before should been done last year at double this SP yet we continue to play this silly game of waiting for the inevitable. At least they have the data to show the place holders prior to raising funds now. Expect an AGM soon or in Aug/Sep when the hammer will come down on raising funds. Once they have proper funding then it is worth buying. Right now absolutely no chance of buying on.